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Hypofractionated Re-irradiation after Maximal Surgical 
Resection for Recurrent Glioblastoma: Therapeutic  
Adequacy and Its Prognosticators of Survival
Jeongshim Lee1,2, Sung Soo Ahn3, Jong Hee Chang4, and Chang-Ok Suh1
Departments of 1Radiation Oncology, 3Radiology, and 4Neurosurgery, Yonsei University College of Medicine, Seoul;
2Department of Radiation Oncology, Inha University Hospital, Incheon, Korea. 
Purpose: To evaluate the adequacy of retreatment, including hypofractionated re-irradiation (HFReRT), after surgery for recur-
rent glioblastoma (GBM) and related prognosticators of outcomes. 
Materials and Methods: From 2011 to 2014, 25 consecutive patients with recurrent (n=17) or secondary (n=7) disease underwent 
maximal surgery and subsequent HFReRT after meeting the following conditions: 1) confirmation of recurrent or secondary 
GBM after salvage surgery; 2) Karnofsky performance score (KPS) ≥60; and 3) interval of ≥12 months between initial radiotherapy 
and HFReRT. HFReRT was delivered using a simultaneous integrated boost technique, with total dose of 45 Gy in 15 fractions to 
the gross tumor volume (GTV) and 37.5 Gy in 15 fractions to the clinical target volume.
Results: During a median follow-up of 13 months, the median progression-free and overall survival (OS) were 13 and 16 months, 
respectively. A better KPS (p=0.026), no involvement of the eloquent area at recurrence (p=0.030), and a smaller GTV (p=0.005) 
were associated with better OS. Additionally, OS differed significantly between risk groups stratified by the National Institutes of 
Health Recurrent GBM Scale (low-risk vs. high-risk, p=0.025). Radiologically suspected radiation necrosis (RN) was observed in 
16 patients (64%) at a median of 9 months after HFReRT, and 8 patients developed grade 3 RN requiring hospitalization.
Conclusion: HFReRT after maximal surgery prolonged survival in selected patients with recurrent GBM, especially those with 
small-sized recurrences in non-eloquent areas and good performance.
Key Words: Recurrent glioblastoma, retreatment, re-irradiation, surgery, survival
INTRODUCTION
Long-term local control of glioblastoma (GBM) is rarely achi-
eved with standard treatments, which include maximal surgi-
cal resection followed by radiotherapy (RT) with concomitant 
and adjuvant temozolomide. Such cases nearly always experi-
ence a relapse within 5 years.1-5 Although a standard of care 
has not been established for recurrent GBM, various re-treat-
ment approaches, including re-operation, re-irradiation, che-
motherapy (CTx), and combined treatment, are used despite 
the increased risks of toxicity and uncertainty regarding sur-
vival advantages.6 
Although re-operation is an effective option for patients with 
small tumor volumes, good Karnofsky performance scores 
(KPSs), no involvement at the eloquent site, and young ages, 
this treatment is indicated for only 10–30% of patients with re-
current GBM.7-10 Re-irradiation with a moderate dose (~40 Gy) 
and conventional fractionation has yielded acceptable com-
plication rates; however, the efficacy of this treatment remains 
undetermined because of the relatively low radiation doses 
administered to GBMs. Recently, hypofractionated RT admin-
istered via intensity modulated RT (IMRT) and/or stereotactic 
RT has improved the outcomes of re-irradiation for recurrent 
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GBM.11-14 However, almost all treated patients, particularly 
those treated with stereotactic radiosurgery (SRS), experienced 
recurrent GBMs with small volumes that could not be differ-
entiated from treatment-related changes, pseudoprogression, 
or radiation necrosis (RN).15 Therefore, a recurrence should 
be pathologically confirmed before subjecting patients with 
recurrent GBM to salvage treatment.
In light of these earlier findings, our institution administers 
hypofractionated re-irradiation (HFReRT) to patients with re-
current GBM who had undergone maximal surgical resection. 
We hypothesized that for selected cases of recurrent GBM, 
this treatment combination likely comprises the most effec-
tive salvage treatment and provides the best chance of survival 
prolongation. In addition, we evaluated the adequacy of HFR-
eRT after maximal surgical resection in patients with recur-
rent GBM. 
MATERIALS AND METHODS
Study design
We prospectively collected and followed all cases of recurrent 
or secondary GBM treated with HFReRT after salvage surgery 
at our institutions between November 2011 and December 
2014. All patients were presented to our institute’s multidisci-
plinary neuro-oncology tumor conference, which included 
neurosurgeon, radiation oncologist, neuro-oncologist, and 
neuro-radiologist. Tumor recurrences were identified by the 
appearance of new contrast-enhanced lesions on T1-weighted 
magnetic resonance imaging (MRI) scans or increase in the 
volumes of enhanced lesions that had been recorded as treat-
ment-related changes after initial treatment. Eventually, a di-
agnosis of recurrent GBM was established via histologic anal-
ysis after salvage surgery, and HFReRT was offered to selected 
patients who met the following inclusion criteria, based on our 
previous work: 1) pathologically confirmed recurrent GBM 
treated with salvage surgery; 2) age of 18−70 years; 3) KPS ≥60 
at the time of referral for HFReRT; and 4) an interval of ≥12 
months between initial RT and HFReRT.16 This study was ap-
proved by our Institutional Review Board (4-2017-0878).
Salvage re-treatment 
Patients with recurrent or secondary GBM underwent maxi-
mal surgical resection of the enhancing lesions identified on 
MRI scans. HFReRT was offered to patients within 4 weeks af-
ter salvage surgery. Each patient underwent a computed to-
mography simulation in the supine position while immobilized 
with a customized thermoplastic mask device. MRI scans at 
recurrence and after salvage surgery for the recurrent tumor 
were transferred to the planning system; after image fusion, 
the gross tumor volume (GTV) was delineated on T1-weighted 
MRI scans, based on the operative cavity and residual contrast 
(gadolinium)-enhanced lesion plus a 0.5-cm margin. The 
clinical target volume (CTV) was defined as the GTV with a 
1−2-cm expansion to account for peritumoral edema on T2 flu-
id-attenuated inversion recovery MRI sequences. HFReRT was 
delivered via helical tomotherapy with 6-MV photons (Tomo-
Therapy, Madison, WI, USA) using a simultaneous integrated 
boost technique. Doses of 45 Gy in 15 fractions and 37.5 Gy in 
15 fractions were delivered to the GTV and CTV, respectively.
Treatment outcomes and prognostic variables
All patients underwent MRI evaluations at 1 month after sal-
vage treatment for recurrent GBM, and every 3 months there-
after. During follow-up, the treatment outcome and toxicity 
assessments included a thorough history taking, physical ex-
amination (particularly the KPS and neurological status), and 
analysis of all available imaging data, including contrast-en-
hanced brain MRI scans. Toxicity after salvage treatment was 
assessed according to the criteria of the Radiation Therapy 
Oncology Group. However, no specific tool was used to assess 
the patients’ neurocognitive status or quality of life. The prima-
ry endpoints for analysis were overall survival (OS) and pro-
gression-free survival (PFS). OS was calculated from the date 
of surgery for recurrence to the date of death from any cause, 
and PFS was measured from the date of recurrence until the 
date of tumor progression or death. The following prognostic 
factors associated with OS were included: age, gender, KPS, 
initial histology, eloquent area involvement at recurrence, ex-
tent of surgery at recurrence, O6-methylguanine-DNA-methyl-
transferase status at recurrence, isocitrate dehydrogenase (IDH) 
mutation at recurrence, tumor volume at recurrence, GTV for 
HFReRT, and interval between RT courses. In addition, we di-
vided patients into prognostic groups using the NIH recurrent 
GBM scale, which is a practical scoring system devised by the 
National Institutes of Health (NIH),9 and assessed OS by group. 
The secondary endpoints included any documented treat-
ment-related toxicity observed during follow-up examina-
tions and on MRI scans. 
       
Statistical analysis
Survival rates were estimated using the Kaplan-Meier method. 
A univariate analysis of risk factors was performed by com-
paring survival rates using the log-rank test. A multivariate anal-
ysis was performed using a Cox regression model with a step-
wise method to identify prognostic factors. A p value <0.05 was 
considered statistically significant. All analyses were performed 
using IBM SPSS, version 20.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient and treatment characteristics
Our study population included 25 patients (11 men, 14 wom-
en) with a median age at recurrence of 45 years (range, 23−61 
years) and median and minimum KPSs of 90 and 60, respec-
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tively. Among all patients, 8 patients had secondary GBM, 
who were initially diagnosed with WHO grade II/III glioma. 
The median recurrent tumor volume was 32 mL (range, 4−90 
mL). All patients underwent surgery for pathologic diagnosis 
and maximal tumor debulking; 15 underwent gross total re-
section (GTR) and 10 underwent subtotal resection, defined 
as the removal of >90% of the contrast-enhanced tumor. All 
patients had received a median postoperative RT dose of 60 
Gy (range, 54−70 Gy) at the time of the initial diagnosis, and 
the median time interval between the initial RT and re-irradi-
ation courses was 30 months (range, 12−72 months; 29 months 
for primary recurrent GBM, 30 months for secondary GBM). 
At the time of HFReRT, the median GTV and CTV were 97 mL 
(range, 21−261 mL) and 270 mL (range, 101−1353 mL), respec-
tively. Thirteen patients received sequential systemic therapy 
with temozolomide after HFReRT. Details of the baseline 
characteristics are described in Table 1. 
Survival and prognostic variables
Patients were followed up for a median of 13 months (range, 
Table 1. Patient and Treatment Characteristics 
Characteristic
All patients (n = 25)
n (%) 
Age (yr)
Median (range)   45 (23–61)  
<45   10 (40)
≥45   15 (60)
Sex 
Male   11 (44)
Female   14 (56)
Initial histology
WHO II glioma     2 (8)
WHO III glioma     6 (24)
GBM   17 (68)
Initial RT dose (Gy) Median (range)   60 (54–70)
Initial CTx
No     7 (28)
Yes   18 (72)
KPS at recurrence Median (range)   90 (60–100)  
Eloquent area involvement at recurrence
No   13 (52)
Yes   12 (48)
Extent of surgery at recurrence
Gross total   15 (58)
Subtotal   10 (42)
MGMT status at recurrence
Unmethylated     9 (36)
Methylated   16 (64)
IDH mutation at recurrence
Present     8 (32)
Absent   14 (56)
Unknown     3 (12)
Tumor volume at recurrence (mL)*
Median (range)   32 (4–90)
<50   15 (60)
≥50   10 (40)
GTV of HFReRT (mL)
Median (range)   97 (21–261)   
<100   14 (56)
≥100   11 (44)
CTV of HFReRT (mL) Median (range) 270 (101–1353)
CTx after HFReRT
No   12 (48)
Yes, sequential   13 (52)
Cumulative dose of RT (Gy)
Median (range) 105 (95.4–115)
<100     2  (8)
≥100   23 (92)
Interval between RT (month)
Median (range)   29 (12–72)  
<30   13 (52)
≥30   12 (48)
WHO, World Health Organization; GBM, glioblastoma; RT, radiotherapy; KPS, Karnofsky performance score; MGMT, O6-methylguanine-DNA-methyltransferase; 
IDH, isocitrate dehydrogenase; GTV, gross tumor volume; CTV, clinical target volume; HFReRT, hypofractionated re-irradiation; CTx, chemotherapy.
*Classified using a tumor volume cut-off value of 50 mL at recurrence, according to the National Institutes of Health recurrent GBM scale. 
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4−41 months) after a recurrence. At the time of the last obser-
vation, 5 patients (20%) remained alive at 15, 16, 22, 28, and 29 
months after recurrence; the other 20 (80%) had died. The me-
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Fig. 1. Kaplan-Meier curves of PFS and OS. PFS, progression-free sur-
vival; OS, overall survival.
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Fig. 2. OS according to the KPS (A), eloquent area involvement at recurrence (B), GTV (C), and CTx after hypofractionated re-irradiation (D). OS, over-
all survival; KPS, Karnofsky performance score; GTV, gross tumor volume; CTx, chemotherapy.
A
C
B
D
p=0.026
p=0.005
p=0.030
p=0.033
dian PFS duration and 1-year PFS rate were 13 months (range, 
1−41 months) and 51.4%, respectively, and the median OS 
duration and 1-year OS rate were 16 months (range, 7−41 
months) and 60%, respectively (Fig. 1). A univariate analysis 
of factors related to OS after a recurrence identified the KPS 
(p=0.026) (Fig. 2A), eloquent area involvement at recurrence 
(p=0.030) (Fig. 2B), GTV at HFReRT (p=0.005) (Fig. 2C), and 
administration of sequential CTx after HFReRT (p=0.033) (Fig. 
2D) as significant factors. In contrast, age (p=0.385), initial his-
tology (p=0.232), the extent of surgery at recurrence (p=0.391), 
IDH mutation status at recurrence (p=0.626), tumor volume 
at recurrence (p=0.075), and interval between RT (p=0.489) 
did not affect OS. All results from the univariate analysis are 
shown in Table 2. In a multivariate stepwise Cox regression 
model analysis, the GTV at HFReRT (≥100 mL vs. <100 mL: 
hazard ratio=3.717, 95% confidence interval: 1.356−10.187, 
p=0.011) was confirmed as an independent prognostic factor 
affecting OS (Table 2). 
 No CTx
 Yes CTx (Temozolomide)
 No CTx-censored
       Yes CTx (Temozolomide)-censored
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Survival according to prognostic groups as defined 
by the NIH recurrent GBM scale
We classified patients into prognostic groups based on the 
NIH recurrent GBM scale, which included the involvement of 
eloquent regions, KPS ≤80, and recurrent tumor volume ≥50 
mL.9 Because our cohort was small, we defined the following 
groups: NIH recurrent GBM scale of 0 or 1 (low-risk group, n= 
14) and NIH recurrent GBM scale of 2 or 3 (high-risk group, 
n=11). The NIH recurrent GBM scale was found to be a signifi-
cant prognosticator of OS (low-risk group vs. high-risk group: 
15 months vs. 10 months, p=0.025) (Fig. 3).
Toxicity
During treatment, no severe acute toxicity events requiring 
the interruption of HFReRT were recorded. During the follow-
up period, corticosteroids, antiepileptic drugs, and mannitol 
were administered in 22 (88%), 22 (88%), and 7 (28%) cases, 
respectively. At a median of 9 months after HFReRT, 16 patients 
(64%) harbored suspected areas of RN, based on gadolinium-
enhanced T1-weighted MRI scans. However, these lesions 
could not be completely differentiated from tumor progression. 
Of these 16 patients, 8 were hospitalized for neurological de-
terioration with suspected grade 3 RN. Grade 3 RN developed 
in 18.8% (3/16) of cases involving an interval of >24 months 
between RT courses and in 55.6% (5/9) of cases with an inter-
val of <24 months (p=0.062). No differences in the incidence 
of grade 3 RN according to GTV and CTV were observed. 
DISCUSSION
According to several studies, a more aggressive local treat-
ment comprising GTR and/or high-dose re-irradiation via ad-
vanced RT techniques may improve the survival of selected 
patients with recurrent GBM.6,7,13,17,18 However, the use of re-ir-
radiation, which is associated with late side effects and tu-
moricidal effects, remains controversial. Accordingly, our in-
stitution has implemented very strict criteria regarding the 
administration of HFReRT to patients with recurrent GBM, as 
we expect that the benefits of salvage HFReRT in terms of in-
creased tumor control would outweigh the costs of treatment-
related toxicity. 
Table 2. Univariate and Stepwise Multivariate Cox Regression Analyses of Prognosticators of OS
Characteristics
Univariate analysis Multivariate analysis†
1-year OS p value HR 95% CI p value
Age (yr)
<45 60.0 0.385 NI
≥45 60.0
Sex
Male 63.6 0.565 NI
Female 57.1
KPS
60–80 41.7 0.026* Ref 0.680
90–100 76.9 0.759 0.204–2.815
Initial histology
Non-GBM 50.0 0.232 NI
GBM 64.7
Eloquent area involvement at recurrence
No 76.9 0.030* Ref 0.584
Yes 41.7 1.381 0.435–4.388
Extent of surgery at recurrence
Gross total 73.3 0.391 NI
Subtotal 40.0
MGMT status at recurrence
Unmethylated 55.6 0.978 NI
Methylated 62.5
IDH mutation at recurrence
Present 62.5 0.626 NI
Absent 57.1
Tumor volume at recurrence (mL)
<50 73.3 0.075 NI
≥50 40.0
GTV of HFReRT (mL)
<100 71.4 0.005* Ref 0.011
≥100 45.5 3.717 1.356–10.187
Interval between RT (month)
<30 61.5 0.489 NI
≥30 58.3
Sequential CTx after HFReRT
No 41.7 0.033* Ref 0.231
Yes, Temozolomide 76.9 0.528 0.185–1.503
OS, overall survival; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance score; GBM, glioblastoma; MGMT, O6-methylguanine-DNA-methyl-
transferase; IDH, isocitrate dehydrogenase; GTV, gross tumor volume; HFReRT, hypofractionated re-irradiation; RT, radiotherapy; CTx, chemotherapy; Ref, refer-
ence; NI, not included.
*Included in the multivariate analysis, †Variables with a p value ≤0.05 were entered in the multivariate regression model in a stepwise manner and were re-
moved at any point if the p value exceeded 0.05.
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Given the uncertainty of a differential diagnosis that includes 
both recurrent GBM and treatment-related lesions such as 
pseudoprogression or RN after initial treatment for malignant 
gliomas,19 we applied HFReRT only to patients with pathologi-
cally confirmed recurrent or secondary GBM. Previous re-irra-
diation series involving patients with non-pathologically con-
firmed recurrent GBM, especially those treated with SRS, might 
have included cases of treatment-related reactions rather than 
true GBM, which might have led to overestimations of the out-
comes.6,13,15,20-23 Next, our study required the total or subtotal re-
moval of all suspected recurrent GBMs with the aim of maxi-
mum debulking prior to HFReRT, which would thus improve 
the efficacy of this treatment given the radio-resistance of re-
current tumors and uncontrolled behaviors of bulky gross tu-
mors in response to radiation.6,7,24,25 Notably, the extent of sur-
gery did not affect survival in the current study, despite previous 
reports that the extent of resection is a well-known predictive 
factor for survival.24,25 This discrepancy may be attributable not 
only to the limited number of patients, but also to the fact that 
upfront HFReRT (i.e., within 4 weeks after salvage re-opera-
tion) may have temporarily controlled the small amount of re-
sidual tumor remaining after subtotal removal, which we de-
fined as the resection of >90% of a tumor.25
The performance status has also been identified as a factor 
affecting the use of HFReRT in patients with recurrent GBM. 
Several studies have reported strong correlations between a 
good performance score and longer survival.16 Given the fun-
damental importance of this factor, particularly in a re-treat-
ment setting, we set a poor KPS (<60) as an exclusion criterion 
to reduce the risks of physical and neurological deterioration 
after treatment. Notably, a higher performance status, no elo-
quent area involvement, and a smaller GTV were identified as 
positive prognostic factors related to OS in the selected pa-
tients who received HFReRT following surgical resection. These 
prognosticators were similar to those used in the abovemen-
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Fig. 3. OS according to prognostic groups, defined according to the NIH 
recurrent glioblastoma scale. OS, overall survival; NIH, National Insti-
tutes of Health.
p=0.025
tioned validated NIH scale to predict outcomes after the sur-
gical resection of recurrent GBM.9 The difference in tumor vol-
umes between the studies (GTV=100 mL vs. tumor volume at 
recurrence=50 mL) was a consequence of the time points used 
to determine the treatment modalities (postoperative status vs. 
preoperative status). Both studies also proposed that the sub-
group of patients with a poor performance and large or dif-
fuse recurrent tumors located in the eloquent brain area might 
benefit from best supportive care, rather than re-treatment. 
Regarding dose fractionation in the context of re-irradiation, 
the prescribed doses in a recent review ranged from 20 Gy to 
45.5 Gy, and the cumulative equivalent radiation doses (in 
2-Gy fractions; EQD2) for both primary and second RT ranged 
from 81.6 Gy to 102.8 Gy.26 In most published studies, the dos-
es prescribed for re-irradiation ranged from 30 Gy to 45 Gy, 
thus maintaining a cumulative EQD2 of approximately 100 Gy. 
More recently, however, advances in conformal radiation tech-
niques, such as stereotactic RT and IMRT, have led to the de-
livery of higher therapeutic re-irradiation doses via hypofrac-
tionation within short treatment courses.26 In such situations, 
we prescribed 45 Gy in 15 fractions (EQD2, 56.25 Gy) to the op-
erative cavity with/without gross residual tumors plus 0.5 cm. 
This was expected to reduce the treatment period along with 
the tumoricidal re-irradiation dose, as most patients with re-
current GBM have a short life expectancy, limited mobility, 
and considerable dependency. 
Studies of surgery or conventional RT for recurrent GBM 
have reported mild or moderate survival benefits. Although 
most studies of surgery for recurrences were affected by a high 
probability of selection bias, the reported median intervals 
from salvage surgery to death remained <12 months,9,10 and 
the survival durations of patients treated with conventional re-
irradiation for recurrent glioma were also <12 months.16,21 In 
the present study, HFReRT after maximal resection yielded a 
median survival duration of 16 months, although the follow-up 
period was short. We attribute these outcomes to a synergistic 
effect for the following reasons: 1) maximal surgical resection 
is the best approach for tumor eradication and 2) compared 
to conventional RT, higher RT dose with a precision technique 
was applied in our HFReRT strategy.
We additionally evaluated the safety of HFReRT after surgi-
cal resection for recurrent GBM. No acute toxicity events were 
recorded during HFReRT, and all patients completed treat-
ment during a median period of 20 days. However, 16 (64%) 
patients developed late toxicities, including 8 cases each of 
grade 2 and grade 3 RN. This considerably high incidence of 
RN in our study, relative to other studies,26 could not complete-
ly be attributed to tumor progression. Re-irradiation is a well-
known factor that contributes to the risk of RN in cases receiv-
ing a cumulative total irradiated dose of >100 Gy, a larger 
irradiated volume, and a higher fractional dose, as well as those 
involving a short interval between RT courses.27,28 Overall, our 
study cases exhibited the following risk factors: a median 
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HFReRT GTV of 97 mL, median CTV of 270 mL, high median 
cumulative dose of 105 mL, and high fraction dose of 3 Gy. 
These results suggest that clinical feasibility of the current re-
treatment protocol should be investigated based on the clear 
evidence indicating late toxicity.
Despite large treated volumes, the current treatment scheme 
encouragingly prolonged survival in our cohort of selected 
patients with recurrent GBM, which was relatively homoge-
nous regarding demographic and treatment characteristics. 
However, we did not address the meaningful benefit of re-
treatment in patients with recurrent GBM in terms of the neg-
ative effects of treatment-related toxicity on the quality of life or 
the caregivers’ burdens during the end-of-life phase.29 Re-treat-
ment for recurrent GBM should always be considered after 
thoroughly discussing the potential advantages and disadvan-
tages with patients and their family. 
We note that our current study was limited by a small cohort 
and the risk of selection bias. Furthermore, our study featured 
some flaws in patient composition. Our cohort comprised of 
patients with both secondary and recurrent GBM, which are 
different diseases; Secondary GBM might have better survival 
outcome. Additionally, our study lacked a comprehensive as-
sessment of toxicity after re-treatment. The retrospective de-
sign precluded our ability to evaluate the quality of life, includ-
ing systemic neurocognitive function, of patients in our cohort. 
Accordingly, our findings must be validated in well-designed 
studies with larger cohorts.
In conclusion, the combined use of HFReRT with maximal 
surgical resection has prolonged the survival of selected pa-
tients with recurrent GBM. This re-treatment strategy was es-
pecially beneficial for patients with smaller-sized recurrent 
GBMs, no eloquent area involvement, and good performance 
scores. However, studies with larger numbers of patients are 
needed to determine the efficacy of this treatment scheme in 
light of the significant risk of RN. 
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